Background. Exposure to lead hazards is a serious health concern for inner-city children. In the United States, the greatest contributor to an elevated lead level is lead exposure in the home. There are federal regulations to protect children in public housing developments from exposure to lead paint. The efficacy of these regulations has not been examined. Methods. We assessed the association between residence in a public housing development and the risk of an elevated blood lead level among high-risk children in New Orleans. We did so by conducting a case-control study among 7121 children age 6 to 71 months who received a screening blood lead test from New Orleans public health clinics in 1998. Results. We found elevated blood lead levels for 29% of children who were screened. Children residing in New Orleans housing developments had lead levels no different from those residing in nondevelopment housing when controlling for housing age, and child's sex and age (odds ratio = 0.93; 95% confidence interval = 0.77-1.1). Conclusions. Despite legislative efforts, public housing does not appear to protect children from elevated lead levels, calling into question the efficacy of existing regulations.
Epidemiology is a peer-reviewed scientific journal that publishes original research on the full spectrum of epidemiologic topics. Journal content ranges from cancer, heart disease and other chronic illnesses to reproductive, environmental, psychosocial, infectious-disease and genetic epidemiology. The journal places special emphasis on theory and methodology, and welcomes commentaries that explore fundamental assumptions or offer provocative dissent.
Wolters Kluwer Health is a leading provider of information for professionals and students in medicine, nursing, allied health, pharmacy and the pharmaceutical industry. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons; electronic information providers, such as Ovid Technologies, Medi-Span and ProVation Medical; and pharmaceutical information providers Adis International and Source®. Wolters Kluwer Health is a division of Wolters Kluwer, a leading multi-national publisher and information services company with annual revenues (2005) of €3.4 billion and approximately 18,400 employees worldwide. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its depositary receipts of shares are quoted on the Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.
This item is part of a JSTOR Collection.
For terms and use, please refer to our
Epidemiology
© 2003 Lippincott Williams & Wilkins